Expansion of the criteria for living donor liver transplantation for hepatocellular carcinoma

Current Opinion in Organ Transplantation

Volumn 21, Issue 2, 2016, Pages 231-237

  Lee, Hae Won ^a   Suh, Kyung Suk ^a  

^a Seoul National University   (South Korea)

Author keywords

advanced hepatocellular carcinoma; biological markers; expected survival; living donor liver transplantation; patient selection

Indexed keywords

TUMOR MARKER;

ADVANCED CANCER; CANCER PROGNOSIS; CANCER RECURRENCE; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; LIVING DONOR; MORPHOMETRICS; OVERALL SURVIVAL; REVIEW; CARCINOMA, HEPATOCELLULAR; LIVER NEOPLASMS; PATIENT SELECTION;

CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; LIVING DONORS; PATIENT SELECTION;

EID: 84960351227     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0000000000000294     Document Type: Review

References (89)

1. Mancuso A, Perricone G. Hepatocellular carcinoma and liver transplantation: state of the art. J Clin Transl Hepatol 2014; 2: 176-181.
2. Menon KV, Hakeem AR, Heaton ND. Review article: liver transplantation for hepatocellular carcinoma - A critical appraisal of the current worldwide listing criteria. Aliment Pharmacol Ther 2014; 40: 893-902.
3. Bartlett A, Heaton N. Hepatocellular carcinoma: defining the place of surgery in an era of organ shortage. World J Gastroenterol 2008; 14: 4445-4453.
4. Bruix J, Sherman M; Practice Guidelines Committee AAftSoLD. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-1236.
5. Suh KS, Lee HW. Liver transplantation for advanced hepatocellular carcinoma: how far can we go?. Hepat Oncol 2015; 2: 19-28.
6. Bismuth H, Chiche L, Adam R, et al. Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients. Ann Surg 1993; 218: 145-151.
7. Iwatsuki S, Starzl TE, Sheahan DG, et al. Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg 1991; 214: 221-228.
8. OGrady JG, Polson RJ, Rolles K, et al. Liver transplantation for malignant disease. Results in 93 consecutive patients. Ann Surg 1988; 207: 373-379.
9. Yokoyama I, Todo S, Iwatsuki S, Starzl TE. Liver transplantation in the treatment of primary liver cancer. Hepatogastroenterology 1990; 37: 188-193.
10. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-699.
11. Azzam AZ. Liver transplantation as a management of hepatocellular carcinoma. World J Hepatol 2015; 7: 1347-1354.
12. Yeh MM, Yeung RS, Apisarnthanarax S, et al. Multidisciplinary perspective of hepatocellular carcinoma: a Pacific Northwest experience. World J Hepatol 2015; 7: 1460-1483.
13. Mazzaferro V, Llovet JM, Miceli R, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009; 10: 35-43.
14. Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001; 33: 1394-1403.
15. Lee KW, Yi NJ, Suh KS. Section 5. Further expanding the criteria for HCC in living donor liver transplantation: when not to transplant: SNUH experience. Transplantation 2014; 97 (Suppl 8): S20-S23.
16. Hemming AW, Cattral MS, Reed AI, et al. Liver transplantation for hepatocellular carcinoma. Ann Surg 2001; 233: 652-659.
17. Jonas S, Bechstein WO, Steinmuller T, et al. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology 2001; 33: 1080-1086.
18. Tamura S, Kato T, Berho M, et al. Impact of histological grade of hepatocellular carcinoma on the outcome of liver transplantation. Arch Surg 2001; 136: 25-30.
19. De Carlis L, Giacomoni A, Lauterio A, et al. Liver transplantation for hepatocellular cancer: should the current indication criteria be changed?. Transpl Int 2003; 16: 115-122.
20. DuBay D, Sandroussi C, Sandhu L, et al. Liver transplantation for advanced hepatocellular carcinoma using poor tumor differentiation on biopsy as an exclusion criterion. Ann Surg 2011; 253: 166-172.
21. Guerrini GP, Pinelli D, Di Benedetto F, et al. Predictive value of nodule size and differentiation in HCC recurrence after liver transplantation. Surg Oncol 2015.
22. Duffy JP, Vardanian A, Benjamin E, et al. Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA. Ann Surg 2007; 246: 502-509.
23. Cillo U, Vitale A, Bassanello M, et al. Liver transplantation for the treatment of moderately or well differentiated hepatocellular carcinoma. Ann Surg 2004; 239: 150-159.
24. Cillo U, Vitale A, Grigoletto F, et al. Intention-To-Treat analysis of liver transplantation in selected, aggressively treated HCC patients exceeding theMilan criteria. Am J Transplant 2007; 7: 972-981.
25. Saborido BP, Diaz JC, de Los Galanes SJ, et al. Does preoperative fine needle aspiration-biopsy produce tumor recurrence in patients following liver transplantation for hepatocellular carcinoma?. Transplant Proc 2005; 37: 3874-3877.
26. Silva MA, Hegab B, Hyde C, et al. Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-Analysis. Gut 2008; 57: 1592-1596.
27. Takada Y, Tohyama T, Watanabe J. Biological markers of hepatocellular carcinoma for use as selection criteria in liver transplantation. J Hepatobiliary Pancreat Sci 2015; 22: 279-286.
28. Clavien PA, Lesurtel M, Bossuyt PM, et al. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol 2012; 13: e11-e22.
29. Yang SH, Suh KS, Lee HW, et al A revised scoring system utilizing serum alphafetoprotein levels to expand candidates for living donor transplantation in hepatocellular carcinoma. Surgery 2007; 141: 598-609.
30. Zheng SS, Xu X, Wu J, et al. Liver transplantation for hepatocellular carcinoma: Hangzhou experiences. Transplantation 2008; 85: 1726-1732.
31. Toso C, Asthana S, Bigam DL, et al. Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the Scientific Registry of Transplant Recipients database. Hepatology 2009; 49: 832-838.
32. Duvoux C, Roudot-Thoraval F, Decaens T, et al. Liver transplantation for hepatocellular carcinoma: a model including alpha-fetoprotein improves the performance of Milan criteria. Gastroenterology 2012; 143: 986-994.
33. Tanaka T, Kurosaki M, Lilly LB, et al. Identifying candidates with favorable prognosis following liver transplantation for hepatocellular carcinoma: data mining analysis. J Surg Oncol 2015; 112: 72-79.
34. Chaiteerakij R, Zhang X, Addissie BD, et al. Combinations of biomarkers and Milan criteria for predicting hepatocellular carcinoma recurrence after liver transplantation. Liver Transpl 2015; 21: 599-606.
35. Toso C, Meeberg G, Hernandez-Alejandro R, et al. Total tumor volume and alpha-fetoprotein for selection of transplant candidates with hepatocellular carcinoma: a prospective validation. Hepatology 2015; 62: 158-165.
36. Suh KS, Cho EH, Lee HW, et al. Liver transplantation for hepatocellular carcinoma in patients who do not meet the Milan criteria. Dig Dis 2007; 25: 329-333.
37. Fujiyama S, Morishita T, Hashiguchi O, Sato T. Plasma abnormal prothrombin (des-gamma-carboxy prothrombin) as a marker of hepatocellular carcinoma. Cancer 1988; 61: 1621-1628.
38. Suehiro T, Sugimachi K, Matsumata T, et al. Protein induced by vitamin K absence or antagonist II as a prognostic marker in hepatocellular carcinoma. Comparison with alpha-fetoprotein. Cancer 1994; 73: 2464-2471.
39. Eguchi S, Takatsuki M, Hidaka M, et al. Predictor for histological microvascular invasion of hepatocellular carcinoma: a lesson from 229 consecutive cases of curative liver resection. World J Surg 2010; 34: 1034-1038.
40. Kaibori M, IshizakiM, Matsui K, Kwon AH. Predictors of microvascular invasion before hepatectomy for hepatocellular carcinoma. J Surg Oncol 2010; 102: 462-468.
41. Shirabe K, Kajiyama K, Abe T, et al. Predictors of microscopic portal vein invasion by hepatocellular carcinoma: measurement of portal perfusion defect area ratio. J Gastroenterol Hepatol 2009; 24: 1431-1436.
42. Fujiki M, Takada Y, Ogura Y, et al. Significance of des-gamma-carboxy prothrombin in selection criteria for living donor liver transplantation for hepatocellular carcinoma. Am J Transplant 2009; 9: 2362-2371.
43. Shimada M, Yonemura Y, Ijichi H, et al. Living donor liver transplantation for hepatocellular carcinoma: a special reference to a preoperative des-gammacarboxy prothrombin value. Transplant Proc 2005; 37: 1177-1179.
44. Shindoh J, Sugawara Y, Nagata R, et al. Evaluation methods for pretransplant oncologic markers and their prognostic impacts in patient undergoing living donor liver transplantation for hepatocellular carcinoma. Transpl Int 2014; 27: 391-398.
45. Taketomi A, Sanefuji K, Soejima Y, et al. Impact of des-gamma-carboxy prothrombin and tumor size on the recurrence of hepatocellular carcinoma after living donor liver transplantation. Transplantation 2009; 87: 531-537.
46. Kaido T, Ogawa K, Mori A, et al. Usefulness of the Kyoto criteria as expanded selection criteria for liver transplantation for hepatocellular carcinoma. Surgery 2013; 154: 1053-1060.
47. Kim JM, Kwon CH, Joh JW, et al. Expanded criteria for liver transplantation in patients with hepatocellular carcinoma. Transplant Proc 2014; 46: 726-729.
48. Kwon CH, Kim DJ, Han YS, et al. HCC in living donor liver transplantation: can we expand the Milan criteria?. Dig Dis 2007; 25: 313-319.
49. Shirabe K, Taketomi A, Morita K, et al. Comparative evaluation of expanded criteria for patients with hepatocellular carcinoma beyond the Milan criteria undergoing living-related donor liver transplantation. Clin Transplant 2011; 25: E491-E498.
50. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420: 860-867.
51. Tan TT, Coussens LM. Humoral immunity, inflammation and cancer. Curr Opin Immunol 2007; 19: 209-216.
52. Lai Q, Lerut JP. Hepatocellular cancer: how to expand safely inclusion criteria for liver transplantation. Curr Opin Organ Transplant 2014; 19: 229-234.
53. Lai Q, Castro Santa E, Rico Juri JM, et al. Neutrophil and platelet-To-lymphocyte ratio as new predictors of dropout and recurrence after liver transplantation for hepatocellular cancer. Transpl Int 2014; 27: 32-41.
54. Motomura T, Shirabe K, Mano Y, et al. Neutrophil-lymphocyte ratio reflects hepatocellular carcinoma recurrence after liver transplantation via inflammatory microenvironment. J Hepatol 2013; 58: 58-64.
55. Na GH, Kim DG, Han JH, et al. Inflammatory markers as selection criteria of hepatocellular carcinoma in living-donor liver transplantation. World J Gastroenterol 2014; 20: 6594-6601.
56. Sullivan KM, Groeschl RT, Turaga KK, et al. Neutrophil-To-lymphocyte ratio as a predictor of outcomes for patients with hepatocellular carcinoma: a Western perspective. J Surg Oncol 2014; 109: 95-97.
57. Yoshizumi T, Ikegami T, Yoshiya S, et al. Impact of tumor size, number of tumors and neutrophil-To-lymphocyte ratio in liver transplantation for recurrent hepatocellular carcinoma. Hepatol Res 2013; 43: 709-716.
58. An HJ, Jang JW, Bae SH, et al. Serum C-reactive protein is a useful biomarker for predicting outcomes after liver transplantation in patients with hepatocellular carcinoma. Liver Transpl 2012; 18: 1406-1414.
59. Pinato DJ, Stebbing J, Ishizuka M, et al A novel and validated prognostic index in hepatocellular carcinoma: the inflammation based index (IBI). J Hepatol 2012; 57: 1013-1020.
60. Zheng Z, Zhou L, Gao S, et al. Prognostic role of C-reactive protein in hepatocellular carcinoma: a systematic review and meta-Analysis. Int J Med Sci 2013; 10: 653-664.
61. Kim YK, Kim SH, Lee SD, et al. Pretransplant absolute monocyte count in peripheral blood predicts posttransplant tumor prognosis in patients undergoing liver transplantation for hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2014; 13: 250-258.
62. Mori S, Choi Y, Park MS, et al. Usefulness of preoperative C-reactive protein and alpha-fetoprotein levels for prognostication of patients with hepatocellular carcinoma after living donor liver transplantation. Hepatogastroenterology 2014; 61: 2353-2358.
63. Yang SH, Suh KS, Lee HW, et al. The role of (18)F-FDG-PET imaging for the selection of liver transplantation candidates among hepatocellular carcinoma patients. Liver Transpl 2006; 12: 1655-1660.
64. Lee JW, Paeng JC, Kang KW, et al. Prediction of tumor recurrence by 18FFDG PET in liver transplantation for hepatocellular carcinoma. J Nucl Med 2009; 50: 682-687.
65. Kornberg A, Kupper B, Tannapfel A, et al. Patients with non[18 F]fludeoxyglucose-Avid advanced hepatocellular carcinoma on clinical staging may achieve long-Term recurrence-free survival after liver transplantation. Liver Transpl 2012; 18: 53-61.
66. Lee SD, Kim SH, Kim YK, et al. (18)F-FDG-PET/CT predicts early tumor recurrence in living donor liver transplantation for hepatocellular carcinoma. Transpl Int 2013; 26: 50-60.
67. Cheung TT, Chan SC, Ho CL, et al. Can positron emission tomography with the dual tracers [11 C]acetate and [18 F]flurodeoxyglucose predict microvascular invasion in hepatocellular carcinoma?. Liver Transpl 2011; 17: 1218-1225.
68. Yao FY, Xiao L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging. Am J Transplant 2007; 7: 2587-2596.
69. Herrero JI, Sangro B, Pardo F, et al. Liver transplantation in patients with hepatocellular carcinoma across Milan criteria. Liver Transpl 2008; 14: 272-278.
70. Silva M, Moya A, Berenguer M, et al. Expanded criteria for liver transplantation in patients with cirrhosis and hepatocellular carcinoma. Liver Transpl 2008; 14: 1449-1460.
71. Toso C, Trotter J, Wei A, et al. Total tumor volume predicts risk of recurrence following liver transplantation in patients with hepatocellular carcinoma. Liver Transpl 2008; 14: 1107-1115.
72. Akamatsu N, Sugawara Y, Kokudo N. Living donor liver transplantation for patients with hepatocellular carcinoma. Liver Cancer 2014; 3: 108-118.
73. Song GW, Lee SG. Living donor liver transplantation. Curr Opin Organ Transplant 2014; 19: 217-222.
74. Lee SG, Hwang S, Moon DB, et al. Expanded indication criteria of living donor liver transplantation for hepatocellular carcinoma at one large-volume center. Liver Transpl 2008; 14: 935-945.
75. Ghobrial RM, Freise CE, Trotter JF, et al. Donor morbidity after living donation for liver transplantation. Gastroenterology 2008; 135: 468-476.
76. Brown RS Jr. Live donors in liver transplantation. Gastroenterology 2008; 134: 1802-1813.
77. Cheah YL, Simpson MA, Pomposelli JJ, Pomfret EA. Incidence of death and potentially life-Threatening near-miss events in living donor hepatic lobectomy: a world-wide survey. Liver Transpl 2013; 19: 499-506.
78. Tamura S, Sugawara Y, Kokudo N. Section 4. Further expanding the criteria for HCC in living donor liver transplantation: the Tokyo University experience. Transplantation 2014; 97 (Suppl 8): S17-S20.
79. Kumaran V. Role of liver transplantation for hepatocellular carcinoma. J Clin Exp Hepatol 2014; 4: S97-S103.
80. Lo CM, Fan ST, Liu CL, et al. Living donor versus deceased donor liver transplantation for early irresectable hepatocellular carcinoma. Br J Surg 2007; 94: 78-86.
81. Fisher RA, Kulik LM, Freise CE, et al. Hepatocellular carcinoma recurrence and death following living and deceased donor liver transplantation. Am J Transplant 2007; 7: 1601-1608.
82. Park MS, Lee KW, Suh SW, et al. Living-donor liver transplantation associated with higher incidence of hepatocellular carcinoma recurrence than deceased-donor liver transplantation. Transplantation 2014; 97: 71-77.
83. Grant RC, Sandhu L, Dixon PR, et al. Living vs. deceased donor liver transplantation for hepatocellular carcinoma: a systematic review and meta-Analysis. Clin Transplant 2013; 27: 140-147.
84. Chan SC. Section 2. Small-for-size liver graft and hepatocellular carcinoma recurrence. Transplantation 2014; 97 (Suppl 8): S7-S10.
85. Pang TC, Lam VW. Surgical management of hepatocellular carcinoma. World J Hepatol 2015; 7: 245-252.
86. Liang W, Wu L, Ling X, et al. Living donor liver transplantation versus deceased donor liver transplantation for hepatocellular carcinoma: a metaanalysis. Liver Transpl 2012; 18: 1226-1236.
87. Wan P, Zhang JJ, Li QG, et al. Living-donor or deceased-donor liver transplantation for hepatic carcinoma: a case-matched comparison exceeding. World J Gastroenterol 2014; 20: 4393-4940.
88. Xiao GQ, Song JL, Shen S, et al. Living donor liver transplantation does not increase tumor recurrence of hepatocellular carcinoma compared to deceased donor transplantation. World J Gastroenterol 2014; 20: 10953-10959.
89. Ninomiya M, Shirabe K, Facciuto ME, et al. Comparative study of living and deceased donor liver transplantation as a treatment for hepatocellular carcinoma. J Am Coll Surg 2015; 220: 297-304.